** Shares of WuXi Biologics fall 3.4% to HK$14.06
** Co says it noted that a meeting in relation to a revised version of a draft bill was held by the U.S. House Committee on Oversight and Accountability on May 15
** Says the bill includes co in the proposed definition of the term “biotechnology company of concern”, which it believes is a preemptive and unjustified designation
** Co says it does not have a human genomics business nor does it collect human genomic data in any of its businesses
** Adds it does not and will not pose a security risk to the United States or any other countries
** Hong Kong shares of WuXi AppTec slip 1.6% and Shanghai stock eases 1.5%
** WuXi Biologics is down 52.4% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Comments